DK3503890T3 - Anvendelse af pridopidin til behandling af dystonier - Google Patents
Anvendelse af pridopidin til behandling af dystonier Download PDFInfo
- Publication number
- DK3503890T3 DK3503890T3 DK17844432.9T DK17844432T DK3503890T3 DK 3503890 T3 DK3503890 T3 DK 3503890T3 DK 17844432 T DK17844432 T DK 17844432T DK 3503890 T3 DK3503890 T3 DK 3503890T3
- Authority
- DK
- Denmark
- Prior art keywords
- pridopidine
- dystonias
- treatment
- Prior art date
Links
- 208000010118 dystonia Diseases 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US201662395319P | 2016-09-15 | 2016-09-15 | |
| PCT/US2017/048458 WO2018039475A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating dystonias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3503890T3 true DK3503890T3 (da) | 2025-01-27 |
Family
ID=61246309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17844432.9T DK3503890T3 (da) | 2016-08-24 | 2017-08-24 | Anvendelse af pridopidin til behandling af dystonier |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11826361B2 (https=) |
| EP (1) | EP3503890B1 (https=) |
| JP (2) | JP7278210B2 (https=) |
| CN (1) | CN110012661A (https=) |
| AU (1) | AU2017315781B2 (https=) |
| BR (1) | BR112019003731A2 (https=) |
| CA (1) | CA3035099C (https=) |
| DK (1) | DK3503890T3 (https=) |
| ES (1) | ES3009437T3 (https=) |
| MX (1) | MX2019002190A (https=) |
| PL (1) | PL3503890T3 (https=) |
| WO (1) | WO2018039475A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| CN115551505B (zh) * | 2020-05-04 | 2026-03-17 | 普瑞尼亚神经治疗有限公司 | 使用选择性s1r激动剂治疗病毒性感染、疾病或病症 |
| KR20250121149A (ko) * | 2022-12-27 | 2025-08-11 | 프리레니아 뉴로테라퓨틱스 엘티디. | 소아 헌팅턴병 치료를 위한 프리도피딘 |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
| US20250281500A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| JP2008501749A (ja) * | 2004-06-08 | 2008-01-24 | ニューロサーチ スウェーデン アクチボラゲット | ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン |
| SE0401465D0 (sv) * | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| SI2146961T1 (sl) | 2007-04-12 | 2014-08-29 | IVAX International GmbH | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
| US8562488B2 (en) * | 2009-10-05 | 2013-10-22 | The Cleveland Clinic Foundation | Systems and methods for improving motor function with assisted exercise |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| US20140037850A1 (en) * | 2012-08-06 | 2014-02-06 | General Electric Company | Corrosion and wear resistant organic coatings |
| PE20160195A1 (es) * | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| CA2993183A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| HRP20251431T1 (hr) | 2017-08-14 | 2026-01-02 | Prilenia Neurotherapeutics Ltd. | Liječenje amiotrofične lateralne skleroze pridopidinom |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
-
2017
- 2017-08-24 WO PCT/US2017/048458 patent/WO2018039475A1/en not_active Ceased
- 2017-08-24 ES ES17844432T patent/ES3009437T3/es active Active
- 2017-08-24 BR BR112019003731A patent/BR112019003731A2/pt not_active IP Right Cessation
- 2017-08-24 CN CN201780066796.2A patent/CN110012661A/zh active Pending
- 2017-08-24 DK DK17844432.9T patent/DK3503890T3/da active
- 2017-08-24 AU AU2017315781A patent/AU2017315781B2/en active Active
- 2017-08-24 CA CA3035099A patent/CA3035099C/en active Active
- 2017-08-24 PL PL17844432.9T patent/PL3503890T3/pl unknown
- 2017-08-24 MX MX2019002190A patent/MX2019002190A/es unknown
- 2017-08-24 JP JP2019531546A patent/JP7278210B2/ja active Active
- 2017-08-24 EP EP17844432.9A patent/EP3503890B1/en active Active
-
2019
- 2019-02-24 US US16/283,784 patent/US11826361B2/en active Active
-
2021
- 2021-05-06 JP JP2021078788A patent/JP7278327B2/ja active Active
-
2023
- 2023-10-19 US US18/489,846 patent/US12564582B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7278327B2 (ja) | 2023-05-19 |
| CA3035099C (en) | 2023-01-17 |
| EP3503890A4 (en) | 2020-05-06 |
| PL3503890T3 (pl) | 2025-03-24 |
| AU2017315781A1 (en) | 2019-04-11 |
| US20240075021A1 (en) | 2024-03-07 |
| JP2019524897A (ja) | 2019-09-05 |
| ES3009437T3 (en) | 2025-03-26 |
| US20190192496A1 (en) | 2019-06-27 |
| CA3035099A1 (en) | 2018-03-01 |
| AU2017315781B2 (en) | 2021-01-28 |
| EP3503890A1 (en) | 2019-07-03 |
| JP2021119189A (ja) | 2021-08-12 |
| WO2018039475A8 (en) | 2018-10-04 |
| BR112019003731A2 (pt) | 2019-07-16 |
| EP3503890B1 (en) | 2024-12-18 |
| JP7278210B2 (ja) | 2023-05-19 |
| CN110012661A (zh) | 2019-07-12 |
| MX2019002190A (es) | 2019-09-11 |
| US12564582B2 (en) | 2026-03-03 |
| US11826361B2 (en) | 2023-11-28 |
| WO2018039475A1 (en) | 2018-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3501542T3 (da) | Esketamin til behandling af depression | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3439635T3 (da) | Formuleringer til behandling af fast tumor | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK4008329T3 (da) | Isoxazolinforbindelser til anvendelse i behandling af demodicose | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom |